Brickell Biotech Inc
F:VCC2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Casio Computer Co Ltd
TSE:6952
|
JP |
|
Coca-Cola Consolidated Inc
NASDAQ:COKE
|
US |
|
S
|
Shagrir Group Vehicle Services Ltd
TASE:SHGR
|
IL |
|
Hyundai Corporation Holdings Co Ltd
KRX:227840
|
KR |
|
Hunting PLC
LSE:HTG
|
UK |
|
T
|
Telus Corp
NYSE:TU
|
CA |
|
Kailong High Technology Co Ltd
SZSE:300912
|
CN |
|
Alina Holdings PLC
LSE:ALNA
|
UK |
|
T
|
Tialis Essential IT PLC
LSE:TIA
|
UK |
Brickell Biotech Inc
EPS (Diluted)
Brickell Biotech Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Brickell Biotech Inc
F:VCC2
|
EPS (Diluted)
-$7
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Brickell Biotech Inc
Glance View
Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 16 full-time employees. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.
See Also
What is Brickell Biotech Inc's EPS (Diluted)?
EPS (Diluted)
-7.5
USD
Based on the financial report for Dec 31, 2022, Brickell Biotech Inc's EPS (Diluted) amounts to -7.5 USD.
What is Brickell Biotech Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
66%
Over the last year, the EPS (Diluted) growth was 66%.
